CAMP logo

CAMP
Calamp Corp.

2,446
Mkt Cap
$230.52M
Volume
85,709.00
52W High
$7.75
52W Low
$1.31
PE Ratio
-1.73
CAMP Fundamentals
Price
$4.44
Prev Close
$4.44
Open
$4.42
50D MA
$4.65
Beta
1.63
Avg. Volume
404,384.29
EPS (Annual)
-$2.65
P/B
4.83
Rev/Employee
$72,875.00
$77.34
Loading...
Loading...
News
all
press releases
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Short Interest Down 14.2% in March
CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) was the target of a large decrease in short interest in March. As of March 31st, there was short interest totaling 414,235 shares, a decrease of 14.2% from the March 15th total of 483,060 shares. Based on an average daily trading...
MarketBeat·7d ago
News Placeholder
More News
News Placeholder
CAMP4 Therapeutics (NASDAQ:CAMP) Upgraded to "Strong-Buy" at Rodman & Renshaw
Rodman & Renshaw upgraded CAMP4 Therapeutics to a "strong-buy" rating in a research report on Tuesday...
MarketBeat·10d ago
News Placeholder
CAMP4 Therapeutics Unveils Gene-Upregulation ASO Platform, Targets SYNGAP1 Clinic Entry in 2H
CAMP4 Therapeutics (NASDAQ:CAMP) outlined its approach to upregulating gene expression using antisense oligonucleotides (ASOs) and provided an update on its lead central nervous system (CNS) program...
MarketBeat·11d ago
News Placeholder
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Rating of "Moderate Buy" by Analysts
CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) has received a consensus rating of "Moderate Buy" from the six ratings firms that are presently covering the firm, Marketbeat Ratings...
MarketBeat·16d ago
News Placeholder
Camp4 Therapeutics Earnings Review: Q4 Summary
read more...
Benzinga·2mo ago
News Placeholder
CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's Why
CAMP4 Therapeutics Corporation (CAMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·3mo ago
News Placeholder
CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's What You Should Know
CAMP4 Therapeutics Corporation (CAMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·7mo ago
<
...
1
>

Latest CAMP News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.